Business Wire (Thu, 8:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,315 people get BIIB articles and Market Currents by email alert.
Get email alerts on BIIB »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Business Wire (Wed, 4:01PM)
-
Business Wire (Tue, 4:30AM)
-
-
-
Business Wire (May 13, 2013)
-
-
-
-
-
-
-
-
-
-
Business Wire (Apr 25, 2013)
-
-
-
-
Tecfidera Raises The Bar For Biogen IdecBrian L. Wilson • Mon, Apr 1 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Biogen: A 'Decimated' Pipeline?Derek Lowe • Tue, Jan 17, 2012 -
Biogen Idec: Q3 Clues To ValueWilliam Meyers • Thu, Nov 3, 2011
-
Biogen Idec: Fairly Priced With A Healthy Balance SheetRon Sommer • Mon, Sep 12, 2011
-
Biogen Idec's CEO Hosts 2012 Analyst Day (Transcript)Tue, Jun 12, 2012 • 1 Comment
-
Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call TranscriptTue, Jan 31, 2012
-
Biogen Idec's CEO Discusses Q3 2011 Results - Earnings Call TranscriptFri, Oct 28, 2011
-
Biogen Idec Inc. - Special CallWed, Oct 26, 2011
-
Biogen Idec's CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Jul 26, 2011
-
Biogen Idec's CEO Discusses Q1 2011 Results - Earnings Call TranscriptThu, Apr 21, 2011
-
Biogen Idec CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Biogen Idec Inc. Q2 2010 Earnings Call TranscriptTue, Jul 20, 2010
-
Biogen Idec, Inc. Q1 2010 Earnings Call TranscriptTue, Apr 20, 2010
-
Biogen Idec, Inc. Q4 2009 Earnings Call TranscriptTue, Feb 9, 2010 • 1 Comment
-
Biogen Idec Inc. Q3 2009 Earnings Call TranscriptTue, Oct 20, 2009
-
Biogen Idec Inc., Q2 2009 Earnings Call TranscriptThu, Jul 16, 2009
-
Business Wire (Thu, 8:00AM)
-
Business Wire (Wed, 4:01PM)
-
Business Wire (Tue, 4:30AM)
-
at CNBC.com (May 14, 2013)
-
Business Wire (May 13, 2013)
-
at CNBC.com (May 9, 2013)
-
at MarketWatch.com (May 9, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at MarketWatch.com (Apr 26, 2013)
-
at CNBC.com (Apr 25, 2013)
-
at MarketWatch.com (Apr 25, 2013)
-
Business Wire (Apr 25, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 22, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at CNBC.com (Apr 20, 2013)
-
at CNBC.com (Apr 18, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at MarketWatch.com (Apr 15, 2013)
BIIB vs. ETF Alternatives
Company Description
Biogen Idec is a global biotechnology company that creates new standards of care in therapeutic areas with high unmet medical needs. Our business strategy is focused on discovering and developing first-in-class or best-in-class products that we can deliver to specialty markets globally.... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Sunday, January 27, 5:30 PM Notable earnings before Monday’s open: BIIB, CAT, NTE Comment! [Earnings]
- Thursday, January 24, 8:40 AM Biogen's (BIIB) longer-lasting multiple sclerosis drug peginterferon beta-1a meets the goals of a Phase III trial, helping to cut patients' risk of relapse by 36% when injected every two weeks, and by 28% when given every four weeks. Peginterferon is a version of Biogen's blockbuster Avonex medicine, which is taken once a week. (PR) Comment! [Healthcare]
- Wednesday, January 16, 3:45 PM Biogen Idec (BIIB -0.2%) and Elan (ELN -0.5%) submit applications to the FDA and EMA requesting labeling updates to Tysabri to expand the indication to include first-line use for people living with relapsing forms of multiple sclerosis who have tested negative for antibodies to the JC virus. If approved, it will allow all anti-JCV antibody negative patients to consider the drug early in the course of treatment, regardless of the level of disease activity or prior treatment history. Comment! [Healthcare]
- Wednesday, January 9, 6:04 PM Teva (TEVA) files a petition with the FDA requesting the agency task an outside panel to evaluate the safety of Biogen's (BIIB) multiple sclerosis drug, BG-12, before approval due to concerns over potential risks to the kidney. The drug is a potential competitor to TEVA's Copaxone, and if the request is granted, the drug's launch could be delayed. 2 Comments [Healthcare]
-
Thursday, January 3, 9:10 AM
Premarket gainers: BGMD +22%. SPWR +16%. ALU +10%. CBMX +10%. FOLD +8%. TASR +6%. LDK +6%. ZGNX +5%.
Losers: MLNX -18%. ALLT -10%. FDO -10%. KERX -6%. BIIB -6%. Comment! [On the Move] - Thursday, January 3, 8:07 AM Biogen Idec (BIIB) -5.8% after reporting the failure of its dexpramipexole drug for treating people with amyotrophic lateral sclerosis (ALS), which is also known as Lou Gehrig's disease and which affects the nerve cells in the brain and spinal cord that control muscle movement. The medicine didn't meet its primary goals of improving "function and survival," nor did it meet any key secondary endpoints. (PR) 2 Comments [On the Move, Healthcare]
- Thursday, December 20, 2012, 12:25 PM Biogen Idec (BIIB -0.2%) says it's collaborating with several leading academic research centers to leverage a range of scientific techniques and disciplines to identify new approaches to treating amyotrophic lateral sclerosis. It is anticipated that coordinating research and sharing results across a number of different disciplines will greatly accelerate the understanding of the mechanisms of the disease and the development of new treatments. Comment! [Healthcare, On the Move]
- Monday, December 10, 2012, 9:54 AM Isis Pharmaceuticals (ISIS +3.1%) clearly has something that Biogen Idec (BIIB +1.3%) likes - the latter adds a third agreement in the companies' partnership, which will now include the development of drugs for three undisclosed targets to treat neurological or neuromuscular disorders. Biogen will pay Isis $30M upfront, another $200M in milestones for each program, and double-digit royalties on drug sales. (PR) 1 Comment [On the Move, Healthcare]
- Wednesday, November 14, 2012, 12:32 PM Baxter (BAX -0.2%) gets initiated at Bernstein this morning with an Outperform, asserting that the threat from Biogen's (BIIB) late-stage hemophilia drug research to BAX's dominant drug, Advate, is overblown. The firm says patients are reluctant to switch treatments, and the area where BIIB's drug looks strongest - treating sudden bleeding episodes - accounts for just 25% of Advate's US sales. Additionally, BAX also has late-stage data on an Alzheimer's drug due next year. Comment! [Healthcare]
- Wednesday, October 31, 2012, 9:48 AM Biogen (BIIB -1%) and Swedish partner Orphan Biovitrum say their Factor VIII Fc Fusion Protein controlled bleeding in patients with Hemophilia A in a Phase III trial. Biogen now plans to file for FDA approval of the treatment in H1 next year and for EU authorization after it completes a study in children. The market for hemophilia A treatments is worth about $5B. (PR) Comment! [Healthcare]
- Thursday, October 25, 2012, 7:18 AM Biogen Idec (BIIB): Q3 EPS of $1.91 beats by $0.32. Revenue of $1.4B (+6% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
- Thursday, October 25, 2012, 12:05 AM Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH Comment! [Earnings]
- Wednesday, October 24, 2012, 5:30 PM Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH 1 Comment [Earnings]
- Thursday, October 18, 2012, 9:05 AM The FDA extends its review of Biogen Idec's (BIIB -2.8%) multiple-sclerosis pill BG-12 by three months, although the agency hasn't requested additional studies. Last week, Biogen said that new data provided more evidence of the the drug's effectiveness in patients with relapsing-remitting MS. Comment! [Healthcare]
- Friday, October 12, 2012, 11:06 AM Biogen Idec (BIIB +1.6%) says new data from Phase III studies evaluating its experimental multiple-sclerosis pill BG-12 showed strong clinical and positive radiological effects in people with relapsing-remitting MS. The data was presented at the 28th Congress of the European Committee for the Treatment and Research of Multiple Sclerosis in Lyon, France. 2 Comments [Healthcare, On the Move]
- Wednesday, September 26, 2012, 8:23 AM Biogen IDEC (BIIB) and partner Swedish Orphan Biovitrum (BIOVF.PK) see positive top-line results from a study of their clotting factor candidate for patients with hemophilia B. The recombinant Factor IX Fc fusion protein was "generally well tolerated" and offers a more long-lasting treatment than current therapies requiring up to three intravenous injections a week. BIIB +2.4% premarket. Comment! [Healthcare, Breaking News, On the Move]
-
- View all 0 replies
-
Michael Bryant
Biogen Idec (BIIB) & Gilead Sciences (GILD) has performed almost the same in the long run. http://yhoo.it/PmgLjg - View all 0 replies
-
- View all 3 replies
-
-
-
- View all 5 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
freefdawatchlist
http://bit.ly/LK63DV Premarket gainer $SRPT (117%), $HZNP (%%), $BIDU (5%), $R, $MNST, $BIIB, $GT, $RF, - View all 0 replies
-
Michael Bryant
The S&P Biotech index has been hot. Biogen (BIIB) & Gilead Sciences (GILD) are two safe plays. - View all 0 replies
-
Michael Bryant
Watch Biogen Idec's (BIIB) & Panera Bread's (PNRA) earnings Tuesday. Watch Caterpiller (CAT) on Wednesday. http://yhoo.it/OhVV2I - View all 0 replies
LATEST REPLIES